L20
Conditions
Interventions
Group 1: Patients suffering from atopic eczema who come to the Dermatology Department of the Bad Bentheim Specialist Clinic for an acute inpatient stay are assessed both on admission (day 1) and on di
Sponsors
Fachklinik Bad Bentheim
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosis Atopic Exzema Acute inpatient stay in the dermatology department of the Bad Bentheim Specialist Clinic
Exclusion criteria
Exclusion criteria: - Exclusion of persons who are affiliated with the sponsor, study director, or the responsible physician - Exclusion of patients who, in the opinion of the medical staff providing information, are unable to accurately understand the content and significance of the study and the questionnaires and to complete them truthfully - Exclusion of patients, who are incapable of giving their informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intra-individual improvement in the level of suffering and quality of life of patients with atopic eczema under light therapy UVB-311nm, UVA-1 or Blue-Light. Assessment using the paper-based questionnaires Patient Benefit Index (PBI), to measure patient-defined treatment goals and benefits, and Dermatology Life Quality Index (DLQI) to measure quality of life, on admission (day 1) and at the end of the acute inpatient stay standard duration of 12 days (day 12). | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in dermatological conditions under therapy and psychological well-being. Assessment using paper-based questionnaires on admission (day 1) and at the end of the acute inpatient stay with a standard duration of 12 days (day 12): Patient Health Questionnaire 9 (PHQ-9) to assess depression, Itch Controlled Days to assess the severity of itching, Generalised Anxiety Disorder 7 (GAD-7) to assess anxiety and WHO-5 to assess well-being. Assessment of the extent and intensity of eczema using the Eczema Area and Severity Index (EASI) and SCORing Atopic Dermatitis (SCORAD) scales on admission (day 1) and discharge (day 12). At discharge, additional assessment of subjective satisfaction with the light therapy UVB-311nm, UVA-1 or Blue-Light. | — |
Countries
Germany
Contacts
Public ContactAthanasios Tsianakas
Fachklinik Bad Bentheim
Outcome results
None listed